Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04552912 · ClinicalTrials.gov registry record · NA
Physical Activity to Improve Patient Reported Outcomes for Adults With Acute Leukemia
A NA study, sponsored by Duke University.
- Completed
- Registry status
- NA
- Development phase
- 49
- Enrollment target
NCT04552912: Completed NA study, sponsored by Duke University.
NCT04552912 is a NA study that has completed, run by Duke University. The registered enrollment target is 49 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04552912, a NA study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- NA
- Development phase
- 49 participants
- Enrollment target
Study Summary
The purpose of this study is to test the efficacy of an evidence-based tailored physical activity program adapted for adults with acute leukemia. Implementation-related process evaluation of the physical activity program will also be assessed.
Primary Outcome
Measured via evaluation on Chair Stand Test (up to 4 points), Gait Speed Test (up to 4 points) and the 4 Test Balance Scale (up to 4 points) scores can range from 0-12 points. Higher scores = better physical function
Interventions
- BEHAVIORAL Build Stamina Program
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2021-01-15 |
| Est. Completion | 2022-09-15 |
| Phase | NA |
What the finished NCT04552912 record still lists
NCT04552912 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Build Stamina Program is the first listed.
NCT04552912 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04552912 about?
NCT04552912 is a clinical study titled "Physical Activity to Improve Patient Reported Outcomes for Adults With Acute Leukemia". The purpose of this study is to test the efficacy of an evidence-based tailored physical activity program adapted for adults with acute leukemia. Implementation-related process evaluation of the physical activity program will also be assessed.
What is the current status of trial NCT04552912?
This trial is currently completed. It is a NA study. The enrollment target is 49 participants. The study started on 2021-01-15. Estimated completion is 2022-09-15.
What interventions are being tested in trial NCT04552912?
The interventions under investigation include: Build Stamina Program (BEHAVIORAL).
Who is sponsoring clinical trial NCT04552912?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04552912's enrollment target sits among peer trials
49 1379th of 2000 higher than 620 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI